Equities analysts expect that Waters Co. (NYSE:WAT) will announce earnings per share (EPS) of $1.74 for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Waters’ earnings, with estimates ranging from $1.69 to $1.80. Waters posted earnings of $1.59 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 9.4%. The firm is expected to report its next earnings report on Tuesday, April 23rd.

According to Zacks, analysts expect that Waters will report full year earnings of $9.35 per share for the current fiscal year, with EPS estimates ranging from $9.27 to $9.45. For the next year, analysts anticipate that the firm will post earnings of $10.63 per share, with EPS estimates ranging from $10.23 to $11.15. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Waters.

Waters (NYSE:WAT) last released its earnings results on Wednesday, January 23rd. The medical instruments supplier reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.23. The business had revenue of $715.00 million for the quarter, compared to analyst estimates of $702.74 million. Waters had a return on equity of 34.18% and a net margin of 24.54%. The business’s revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.51 earnings per share.

Several equities analysts have recently commented on WAT shares. Goldman Sachs Group lowered Waters from a “neutral” rating to a “sell” rating and set a $200.83 price target on the stock. in a research note on Sunday, December 9th. Barclays cut their price target on Waters from $200.00 to $190.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 24th. Zacks Investment Research lowered Waters from a “buy” rating to a “hold” rating in a research note on Monday, January 7th. BTIG Research raised their price target on Waters to $260.00 and gave the company a “buy” rating in a research note on Thursday, January 24th. Finally, JPMorgan Chase & Co. cut their price target on Waters from $200.00 to $185.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 24th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $208.99.

Shares of Waters stock opened at $232.35 on Tuesday. The firm has a market cap of $17.50 billion, a PE ratio of 28.03, a PEG ratio of 2.28 and a beta of 1.17. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.01 and a current ratio of 2.26. Waters has a 12 month low of $167.93 and a 12 month high of $233.48.

In related news, SVP Michael C. Harrington sold 1,131 shares of the firm’s stock in a transaction dated Friday, December 14th. The stock was sold at an average price of $189.53, for a total transaction of $214,358.43. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Terrence P. Kelly sold 21,028 shares of the firm’s stock in a transaction dated Tuesday, December 11th. The shares were sold at an average price of $190.07, for a total value of $3,996,791.96. Following the sale, the senior vice president now directly owns 9,541 shares in the company, valued at approximately $1,813,457.87. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 97,249 shares of company stock worth $20,981,857. 0.98% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Great Lakes Advisors LLC purchased a new position in shares of Waters in the third quarter worth about $465,000. BTIM Corp. raised its position in Waters by 2.8% during the fourth quarter. BTIM Corp. now owns 289,518 shares of the medical instruments supplier’s stock valued at $54,618,000 after acquiring an additional 7,775 shares in the last quarter. Stevens Capital Management LP raised its position in Waters by 945.8% during the third quarter. Stevens Capital Management LP now owns 22,087 shares of the medical instruments supplier’s stock valued at $4,300,000 after acquiring an additional 19,975 shares in the last quarter. American Century Companies Inc. raised its position in Waters by 47.0% during the third quarter. American Century Companies Inc. now owns 22,737 shares of the medical instruments supplier’s stock valued at $4,426,000 after acquiring an additional 7,270 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in Waters by 4.2% during the third quarter. Bank of New York Mellon Corp now owns 4,542,036 shares of the medical instruments supplier’s stock valued at $884,244,000 after acquiring an additional 183,060 shares in the last quarter. 96.14% of the stock is owned by institutional investors and hedge funds.

Waters Company Profile

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Recommended Story: What is the Stochastic Momentum Index (SMI)?

Get a free copy of the Zacks research report on Waters (WAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.